MedTrace Logo

Efficacy of COVID-19 Vaccination in Patients With Multiple Sclerosis Treated With Immune Modulating Medication

NCT04796584 · Status: TERMINATED · Type: OBSERVATIONAL · Enrollment: 20

Last updated 2023-04-03

No results posted yet for this study

Summary

The primary objective is to determine whether the use of immunomodulating medications have an impact on the ability to mount and sustain an immune response to SARS-CoV-2 spike protein following mRNA vaccination in patients with MS when compared to healthy controls not receiving immunomodulating medications.

We hypothesize that the use of immunomodulators in MS patients may eliminate or reduce the level of protective immune response, and/or shorten the duration of the protective response.

Conditions

Interventions

OTHER

Analysis of cell-mediated and antibody-mediated immunity to SARS-CoV-2 virus

mRNA vaccination for SARS-CoV-2 is not provided by the study

Sponsors & Collaborators

  • Providence Health & Services

    lead OTHER

Principal Investigators

  • Stanley Cohan, MD PhD · Providence Health & Services

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-07-11
Primary Completion
2022-10-04
Completion
2022-10-25

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04796584 on ClinicalTrials.gov